Collaboration AgreementADAP announced a multi-faceted collaboration agreement with Galapagos for uza-cel, which includes initial payments of $100 million and eligibility to receive $565 million in additional payments, securing necessary funding for the launch of afami-cel.
FDA ApprovalThe potential FDA approval for Afamitresgene autoleucel (afami-cel) in relapse/refractory synovial sarcoma could make it the first engineered T-cell therapy on the market for a solid tumor cancer.
Manufacturing EfficiencyUnder the GLPG platform, manufacturing of the engineered cell product is completed with a median vein-to-vein time of seven days, increasing the speed with which patients can be treated while also potentially improving the viability and fitness of the TCR T-cells.